SeIf-Assessment

SeIf-Assessment
Fundamentals
What is a Biologic?
What is the Difference Between a Biosimilar and a Generic?
The FDA Criteria Surrounding Biosimilar Approval, Manufacturing and Naming
Interchangeability and Pharmacy-level Substitution
Cases
Rheumatology
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis?
When to Switch? Biologically-Experienced Patients with Spondyloarthritis
Considering Biosimilars in Patients Failing their Initial Biologic
Gastroenterology
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
Thinking about Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic Therapy
What Can You Expect When an Ulcerative Colitis Patient is Switched from a Reference Biologic to a Biosimilar?
Dermatology
Innovator or Biosimilar for a Patient with Psoriasis
When to Switch? Biologically-Experienced Psoriasis Patients
Switching Between Biologics – Is a Biosimilar an Option?
Activity Faculty
Home

This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.